Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006
|
|
- Eileen Byrd
- 5 years ago
- Views:
Transcription
1 Available online at Diagnostic Microbiology and Infectious Disease 61 (2008) Mycology Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006 Yun-Liang Yang a, An-Huei Wang b, Chih-Wei Wang b, Wei-Ting Cheng b, Shu-Ying Li c, Hsiu-Jung Lo b, TSARY Hospitals a Department of Biological Science and Technology, National Chiao Tung University, Hsinchu 300, Taiwan, ROC b Division of Clinical Research, National Health Research Institutes, Zhunan Town, Miaoli County 350, Taiwan, ROC c Division of Laboratory Research and Development, Center for Disease Control, Taipei 115, Taiwan, ROC Received 27 October 2007; accepted 16 January 2008 Abstract Susceptibilities to amphotericin B and fluconazole of 964 Candida isolates collected in Taiwan Surveillance of Antimicrobial Resistance of Yeasts in 2006 were determined. There were 419 (43.5%) Candida albicans, 246 (25.5%) Candida tropicalis, 211 (21.9%) Candida glabrata, 62 (6.4%) Candida parapsilosis, 14 (1.5%) Candida krusei, and 12 (1.2%) others. Interestingly, 16 of the 17 amphotericin B-resistant isolates were non-albicans Candida species. The resistant rate to amphotericin B has decreased from 2.5% in 2002 to 1.8% in On the other hand, there were 132 C. tropicalis, 14 C. krusei, 10 C. albicans, and 9 C. glabrata isolates that had MICs to fluconazole 64 μg/ml. The prevalence of isolates with such high MICs was significantly higher than that in 2002 (17.1% versus 1.9%). Our results further indicate that most of the isolates with MICs to fluconazole 64 μg/ml exhibited the trailing phenomenon Elsevier Inc. All rights reserved. Keywords: Candida; Susceptibility; Resistance 1. Introduction Because of alterations in immune status and invasive hospital procedures (White et al., 1998; Yang and Lo, 2001), infections caused by opportunistic pathogens, such as yeasts, are becoming important causes of morbidity and mortality in immunocompromised patients. In the past 2 decades, nosocomial yeast infections have increased significantly worldwide. For example, the prevalence of nosocomial candidemia increased 27-fold from 1981 through 1993 at a major hospital in Taiwan (Chen et al., 1997; Hung et al., 1996). In the United States, yeast infection also ranks as the 4th most common cause of nosocomial bloodstream infection (Wisplinghoff et al., 2004). Several antifungal drugs have been applied to render the situation, and as a Corresponding author. Tel.: x35516; fax: address: hjlo@nhri.org.tw (H.-J. Lo). result of broad prophylactic usages and long-term treatments with those drugs, the prevalence of drug resistance has become an important issue in various yeast infections, which have profound effects on human health (Marr et al., 2001; Pfaller et al., 2003; Yang et al., 2004b). Candida species have various degrees of susceptibility to frequently used antifungal drugs. For instance, Candida lusitaniae is relatively resistant to amphotericin B (Hadfield et al., 1987). Candida krusei is intrinsically resistant to fluconazole, and Candida glabrata is less susceptible or has a higher MICs to it than other Candida species (Akova et al., 1991; Orozco et al., 1998; Yang et al., 2004b). This phenomenon illustrates the importance of identification and surveillance of Candida species in the clinical settings. In 1999 and again in 2002, 2 national surveys in Taiwan Surveillance of Antimicrobial Resistance of Yeasts (TSARY) have been conducted. The drug susceptibilities of the 632 and 909 isolates collected in 1999 and 2002, respectively, have been determined (Yang et al., 2004b, 2005b). Among them, 0.5% (1999) and 2.5% (2002) were resistant to /$ see front matter 2008 Elsevier Inc. All rights reserved. doi: /j.diagmicrobio
2 176 Y.-L. Yang et al. / Diagnostic Microbiology and Infectious Disease 61 (2008) amphotericin B. There were 8.4% of the isolates in 1999 that had MICs to fluconazole 64 μg/ml, whereas only 1.9% in 2002 (Yang et al., 2004b, 2005b). In 2006, a follow-up survey was taken place, and 964 Candida isolates were collected and analyzed. The article is to report the result of the susceptibilities to antifungal drugs of Candida species in TSARY 2006 and the trends of the resistance in Taiwan from 1999 to Materials and methods 2.1. Organisms and media Yeast isolates were collected according to previous studies (Lo et al., 2001; Yang et al., 2005b) from the 22 hospitals participating in TSARY from July to September in Each hospital was asked to submit all yeast pathogens from blood and the first 10 Candida albicans and 40 non-albicans Candida species isolates from nonsterile sites. In principle, only 1 isolate was accepted from each specimen. Nevertheless, when there were multiple species isolated from 1 specimen, 1 isolate from each species was analyzed. All the collected isolates were stored frozen at 70 C in bead-containing Microbank cryovials (Pro- Lab Diagnostics, Austin, TX). After their arrival at the laboratory at National Health Research Institutes (NHRI), Taiwan, ROC, these isolates were 1st subcultured on Sabouraud dextrose agar (Becton Dickinson, Cockeysville, MD) to assess the purity and identification. Pure isolates were labeled and stored in vials containing 50% glycerol at 70 C awaiting further analyses Identification The identifications of the isolates were reassessed in the laboratory at the NHRI. The identification procedure for the yeast isolates was modified based on our previous report (Lo et al., 2001). All isolates were subjected to API-32C (biomérieux, St. Louis, MO). The VITEK Yeast Biochemical Card (YBC, biomérieux) would then be used for the identification of the isolates when the API-32C showed less than 90% confidence and for the isolates whose information was inconsistent to that provided by the hospitals. The sequence of internal transcribed spaces of ribosomal DNA (Leaw et al., 2006, 2007) was applied for further assessment when both API-32C and YBC failed Antifungal susceptibility testing The MICs to amphotericin B and to fluconazole of each isolate were determined by the same in vitro antifungal susceptibility testing as those in TSARY 1999 and TSARY 2002 (Yang et al., 2004b, 2005b), according to the guidelines of M27A published in 1997 by the Clinical and Laboratory Standards Institute (CLSI, 1997). The RPMI medium 1640 ( ) provided by Gibco BRL was used for the testing. Strains from American Type Culture Collection including C. albicans (ATCC 90028), C. krusei (ATCC 6258), and Candida parapsilosis (ATCC 22019) were used as the standard controls. The final growth of each isolate was measured by Biotrak II plate reader (Amersham Biosciences, Cambridge, UK) after incubation at 35 C for 48 h. The MICs of some isolates were also measured by Etest (AB BIODISK, Solna, Sweden) to assess the results of the broth microdilution method. The MICs to amphotericin B and to fluconazole were defined as the MICs of drugs capable of reducing the turbidity of cells to greater than 95% and 50%, respectively. For susceptibility to amphotericin B, isolates with MIC 2 μg/ml were considered to be resistant, and those with MIC 1 μg/ml were susceptible. For susceptibility to fluconazole, isolates with MIC 64 μg/ml were considered to be resistant, whereas those with MIC 8 μg/ml were susceptible. Isolates with MICs falling in between (16 32 μg/ml) were susceptible dose dependent. The MICs of 50% and 90% of the total population were defined as MIC 50 and MIC 90, respectively. Among the phenomena associated with resistance, trailing describes the reduced but persistent growth that some isolates exhibit at drug concentrations above the MIC in broth dilution tests with azole antifungal agents, such as fluconazole (Lee et al., 2004). When the MIC of an isolate measured after 48-h incubation is approximately 4-fold higher than that at the 24-h point (Arthington-Skaggs et al., 2002), the isolate is defined to have trailing growth Database and analysis The database for this study contained the characteristic information of each submitted isolate: hospital origin, location and type of the hospital, and identification and source of the isolate. The statistic significance of the differences in frequencies and proportions was determined by the χ 2 test with Yates' correction. 3. Results and discussion 3.1. Distribution of Candida species The distribution of Candida species in TSARY 2006 (Table 1) was similar to that of 2 previous surveys in 1999 and 2002 (Yang et al., 2004b, 2005a). C. albicans was the most frequently isolated species, accounting for 43.5% of the total isolates. Candida tropicalis (25.5%) and C. glabrata (21.9%) were the 2 most frequently isolated non-albicans Candida species, followed by C. parapsilosis (6.4%), C. krusei (1.5%), and others (1.2%). When classified according to the sources (Table 1), there were 406 (42.1%) isolates from urine, 158 (16.4%) from sputum, 145 (15%) from blood, 43 (4.5%) from wound, 40 (4.1%) from pus, 40 (4.1%) from catheter tip, 38 (4%) from ascites, and 94 (9.8%) from other 45 different sites. Different Candida species had various prevalence in different body sites. Although C. albicans was still the most
3 Y.-L. Yang et al. / Diagnostic Microbiology and Infectious Disease 61 (2008) Table 1 The distribution of Candida species from different sources Sources C. albicans C. tropicalis C. glabrata C. parapsilosis C. krusei Others Total Urine (42.1) a Sputum (16.4) Blood (15.1) Wound (4.5) Pus (4.1) Tip b (4.1) Ascites c (3.9) Others (9.8) Total 419 (43.5) 246 (25.5) 211 (21.9) 62 (6.4) 14 (1.5) 12 (1.2) 964 a Number of isolates (percentage). b Catheter tips. c Body fluid, not urinary ascites or pus. common single species (56.6%) causing candidemia in our study as well as others' (Cheng et al., 2004; Peman et al., 2005; Pfaller et al., 2007a; Yang et al., 2006), the prevalence of non-albicans Candida species had increased. Though C. tropicalis was the most common non-albicans Candida species in our collection, C. glabrata was the most common one from urine (145/277, 52.3%). The majority of C. glabrata (68.7%) was isolated from urine samples, consistent with the previous reports that C. glabrata is 2nd only to C. albicans as a cause of candiduria (Pfaller et al., 1999; Yang et al., 2004b) Susceptibilities to amphotericin B of Candida species The range of MICs to amphotericin B of the 964 isolates was from to 2 μg/ml (Table 2). C. krusei was less susceptible to amphotericin B than any other species because the MIC 50 of this species was 1 μg/ml. The overall resistant rate to amphotericin B has decreased from 2.5% in TSARY 2002 (Yang et al., 2005b) to 1.8% in TSARY In recent years, fungal infections caused by non-albicans Candida species have increased dramatically (Abi-Said et al., 1997; Slavin et al., 1995; Walsh et al., 2004). The phenomenon was also reflected in the distribution of resistant isolates in others' (Slavin et al., 1995; Walsh et al., 1998) as well as our studies. All 3 amphotericin B-resistant isolates in TSARY 1999 were non-albicans Candida species (Yang et al., 2004b). Furthermore, 20 of the 23 amphotericin B-resistant isolates in TSARY 2002 were also non-albicans Candida species (Yang et al., 2005b). Of the 17 amphotericin B-resistant isolates in TSARY 2006, 16 were non-albicans Candida species. They consisted of 12 C. tropicalis, 2 C. krusei, and 1 each of C. glabrata and Candida curvatus. The prevalence of amphotericin B resistance of C. krusei (14.3%) or C. tropicalis (4.9%) was significantly higher than that of C. glabrata (0.5%) or C. albicans (0.2%) (P b 0.05). Among the frequently isolated non-albicans Candida species, no amphotericin B-resistant isolate of C. parapsilosis was detected in this study (Table 2), as well as in the 2 previous TSARYs (Yang et al., 2004b, 2005b). A total of 2, 2, and 5 C. lusitaniae were collected in TSARY 1999, 2002, and 2006, respectively. Up-to-date amphotericin B resistance of C. lusitaniae is not an issue for concern since all 9 C. lusitaniae was susceptible to amphotericin B. The MIC 50 and MIC 90 of those isolates were 0.25 and 1 μg/ml, respectively Susceptibilities to fluconazole of Candida species from different sources For the susceptibility to fluconazole, a total of 756 (78.4%), 43 (4.5%), and 165 (17.1%) isolates had MICs 8, 16 to 32, and 64 μg/ml, respectively. The MIC 50 and MIC 90 of these isolates were 1 and 64 μg/ml, respectively. Interestingly, among the isolates with MICs 64 μg/ml, those from sputum (27.2%) appear to have a higher ratio than Table 2 The susceptibility to amphotericin B of Candida species MICs (μg/ml) C. albicans C. tropicalis C. glabrata C. parapsilosis C. krusei Others Total (3.8) a 0 4 (1.9) (8.3) 21 (2.2) (50.8) 45 (18.3) 49 (23.2) 23 (37.1) 0 6 (50) 336 (34.8) (31.9) 126 (51.2) 113 (53.6) 29 (46.8) 5 (35.7) 2 (16.7) 409 (42.4) 1 55 (13.1) 63 (25.6) 44 (20.8) 10 (16.1) 7 (50) 2 (16.7) 181 (18.8) 2 1 (0.2) 12 (4.9) 1 (0.5) 0 2 (14.3) 1 (8.3) 17 (1.8) Total MIC MIC a Number of isolates (percentage).
4 178 Y.-L. Yang et al. / Diagnostic Microbiology and Infectious Disease 61 (2008) those from ascites (7.9%), wound (11.6%), blood (13.1%), and urine (17.7%) (P = 0.05) (Table 3). When comparisons were made among species, there were distinct variations in the fluconazole susceptibility. Of the 5 common Candida species, all C. krusei had MICs 64 μg/ ml. In contrast, none of the C. parapsilosis did. These results were consistent with previous reports (Akova et al., 1991; Pfaller et al., 2000, 2004; Yang et al., 2004a, 2005b). Furthermore, susceptibilities among different species from blood also varied. All C. albicans, C. glabrata, and C. parapsilosis were susceptible to fluconazole, whereas 18 of the 32 (56.3%) C. tropicalis isolates had MICs 64 μg/ml (Table 3). Interestingly, C. glabrata having MICs to fluconazole 64 μg/ml was lower than what has been reported in other geologic areas (Fleck et al., 2007; Pfaller et al., 2007b; St Germain et al., 2001). In the 3 TSARYs, the portions of isolates having MICs 64 μg/ml were 8.3%, 1.6%, and 4.3% isolates from 1999, 2002, and 2006, respectively. It has been reported that continuous exposure to azoles seems to have a major impact on developing resistance to fluconazole in Candida species, especially for C. glabrata (Kontoyiannis, 2002). Therefore, our previous observation that only 13% of the candidemia 92 patients had prior fluconazole treatments (Cheng et al., 2004) may explain the low fluconazole-resistant C. glabrata in Taiwan Trailing growth Among the phenomena associated with resistance, trailing describes the reduced but persistent growth that some isolates exhibit at drug concentrations above the MIC in broth dilution tests with azole antifungal agents, such as fluconazole (Lee et al., 2004). Trailing may interfere the observation of resistance level in vivo (Arthington-Skaggs et al., 2002). Thus, we have also determined whether those 165 isolates with MICs 64 μg/ml to fluconazole exhibit Table 3 The susceptibility to fluconazole of Candida species from different sources MICs (μg/ml) C. albicans C. tropicalis C. glabrata C. parapsilosis C. krusei Others Total Urine (95.3) a 53 (48.6) 117 (80.7) 13 (100) 0 5 (100) 311 (76.6) (0.9) 22 (15.2) (5.7) 64 6 (4.7) 55 (50.5) 6 (4.1) 0 5 (100) 0 72 (17.7) Subtotal Sputum 8 69 (98.6) 25 (38.5) 13 (68.4) 2 (100) (69) (1.4) 0 5 (26.3) (3.8) (61.5) 1 (5.3) 0 2 (100) 0 43 (27.2) Subtotal Blood 8 82 (100) 10 (31.2) 16 (80) 9 (100) 0 1 (100) 118 (81.4) (12.5) 4 (20) (5.5) (56.3) (100) 0 19 (13.1) Subtotal Wound 8 21 (100) 2 (3.3) 5 (83.3) 5 (100) 0 3 (75) 36 (83.7) (16.7) (25) 2 (4.7) (66.7) (100) 0 5 (11.6) Subtotal Pus 8 19 (95) 4 (44.4) 2 (100) 6 (100) 0 1 (100) 32 (80) (5) 5 (55.6) (100) 0 8 (20) Subtotal Tip b 8 18 (90) 7 (53.8) 2 (66.7) 4 (100) (77.5) (7.7) (2.5) 64 2 (10) 5 (38.5) 1 (33.3) (20) Subtotal Ascites c 8 24 (100) 5 (71.4) 4 (100) 2 (100) (92.1) (28.6) (100) 0 3 (7.9) Subtotal Others 8 51 (96.2) 2 (40) 10 (83.4) 20 (95.2) (100) 84 (89.4) (1.9) (8.3) 1 (4.8) (3.2) 64 1 (1.9) 3 (30) 1 (8.3) 0 2 (100) 0 7 (7.4) Subtotal All (97.1) 108 (43.9) 169 (80.1) 61 (98.4) 0 11 (91.7) 756 (78.4) (0.5) 6 (2.4) 33 (15.6) 1 (1.6) 0 1 (8.3) 43 (4.5) (2.4) 132 (53.7) 9 (4.3) 0 14 (100) (17.1) Total a Number of isolates (percentage). b Catheter tips. c Body fluid, not urinary ascites or pus.
5 Y.-L. Yang et al. / Diagnostic Microbiology and Infectious Disease 61 (2008) Table 4 The distribution of trailing growth of Candida species with MICs greater than 64 μg/ml Sources C. albicans trailing, and the results are summarized in Table 4. High percentage (64.8%) of those isolates indeed exhibited the trailing phenomenon. When classified according to species, 72.7% (96/132) C. tropicalis, 70% (7/10) C. albicans, and 44.4% (4/9) C. glabrata isolates exhibited the trailing phenomenon, whereas none of the C. krusei isolates did Conclusion C. glabrata C. krusei C. tropicalis Subtotal Total No Yes No Yes No Yes No Yes No Yes Urine Sputum Blood Pus Ascites Wound Tip Others Total In TSARY 1999, there were 14.7% C. tropicalis isolates having MICs 64 μg/ml (Yang et al., 2004b). In contrast, none of the 244 C. tropicalis from TSARY 2002 had MICs 64 μg/ml (Yang et al., 2005b). Surprisingly, in TSARY 2006, among the 246 C. tropicalis isolates, 132 (53.7%) had MICs 64 μg/ml. Recently, we have reported an association between fluconazole susceptibility and genetic relatedness among C. tropicalis isolates from TSARY 1999 (Chou et al., 2007; Wang et al., 2007). The DST140 was a predominant type of C. tropicalis isolates among those having MICs 64 μg/ml in TSARY 1999 (Chou et al., 2007). Furthermore, none of the 17 tested fluconazolesusceptible C. tropicalis isolates collected from TSARY 2002 were DST140 type (Chou et al., 2007). Interestingly, our preliminary result showed that DST140 was detected again among C. tropicalis isolates collected in TSARY This result may explain the dramatic fluctuation in fluconazole susceptibility among 3 TSARYs. Whether this is an endemic problem requires further investigation. The increasing rate of reduced susceptibility to fluconazole in C. tropicalis has considerable clinical importance, because this species is 1 of the most frequently isolated nonalbicans Candida species (Cheng et al., 2004; Hung et al., 2005; Lo et al., 2005; Pfaller et al., 2000; Prasad et al., 1999). Furthermore, C. tropicalis develops drug resistance in the presence of fluconazole much more rapidly than C. albicans (Barchiesi et al., 2000; Calvet et al., 1997). In addition, C. krusei isolates with high MICs are also closely related (Chou et al., 2007; Wang et al., 2007). These findings may explain why, to fluconazole, C. tropicalis has a higher rate to have MICs 64 μg/ml than C. albicans. Here we have identified that 72.7% (96/132) C. tropicalis exhibited the trailing phenomenon by a definition that the MIC of an isolate after 48-h incubation is 4-fold higher than that at the 24-h point. Nevertheless, whether the remaining 36 (14.6%) C. tropicalis isolates are truly resistant requires further investigation. Acknowledgments The authors would like to thank Bristol Myers Squibb (New Brunswick, NJ) and Pfizer (New York, NY) for supplying the amphotericin B and fluconazole, respectively. They would also like to acknowledge Dr. Y.C. Chen for her assistance and helpful suggestion. They also thank the 22 participating hospitals for providing clinical isolates and information regarding those isolates. They are Asia East Memorial Hospital, Buddhist Tzu-Chi General Hospital, Chang Gung Memorial Chiayi Christian Hospital, Hospital at Kaohsiung, Chang-Hwa Christian Hospital, Cheng Ching Hospital, Chung Shan Medical Dental College Hospital, Kaohsiung Military Hospital, Kaohsiung Medical College Chung-Ho Memorial Hospital, Kuan-Tien General Hospital, Lo-Hsu Foundation Lo-Tung Poh Ai Hospital, Miin Sheng General Hospital, National Cheng Kung University Hospital, Show Chwan Memorial Hospital, Sin-Lau Christian Hospital, St. Mary Hospital, Taipei Municipal Chung Hsiao Hospital, Taipei Municipal Hoping Hospital, Veterans General Hospital-Taichung, Veterans General Hospital-Kaohsiung, Zen Ai General Hospital, and Tungs' Taichung NetroHarbor Hospital, Sha Lu branch. We thank Dr. T.L. Lauderdale and Mr. S.H. Hsu for their technical assistance. This study was supported by the grant NHRI CL-096-PP07. References Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24: Akova M, Akalin HE, Uzun O, Gur D (1991) Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis 10: Arthington-Skaggs BA, Lee-Yang W, Ciblak MA, Frade JP, Brandt ME, Hajjeh RA, Harrison LH, Sofair AN, Warnock DW (2002) Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 46: Barchiesi F, Calabrese D, Sanglard D, Falconi DF, Caselli F, Giannini D, Giacometti A, Gavaudan S, Scalise G (2000) Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother 44: Calvet HM, Yeaman MR, Filler SG (1997) Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother 41: Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT (1997) Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to Infect Control Hosp Epidemiol 18:
6 180 Y.-L. Yang et al. / Diagnostic Microbiology and Infectious Disease 61 (2008) Cheng MF, Yu KW, Tang RB, Fan YH, Yang YL, Hsieh KS, Ho M, Lo HJ (2004) Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to Diagn Microbiol Infect Dis 48: Chou HH, Lo HJ, Chen KW, Liao MH, Li SY (2007) Multilocus sequence typing of Candida tropicalis shows clonal cluster enriched in isolates with resistance or trailing growth of fluconazole. Diagn Microbiol Infect Dis 58: Clinical and Laboratory Standards Institute (formally NCCLS) (1997) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. M27A. Wayne, PA: CLSI. Fleck R, Dietz A, Hof H (2007) In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother 59: Hadfield TL, Smith MB, Winn RE, Rinaldi MG, Guerra C (1987) Mycoses caused by Candida lusitaniae. Rev Infect Dis 9: Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC (1996) Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc 95: Hung CC, Yang YL, Lauderdale TL, McDonald LC, Hsiao CF, Cheng HH, Ho YA, Lo HJ (2005) Colonization of human immunodeficiency virusinfected outpatients in Taiwan with Candida species. J Clin Microbiol 43: Kontoyiannis DP (2002) Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 34: Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP, Chang TC (2006) Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microbiol 44: Leaw SN, Chang HC, Barton R, Bouchara JP, Chang TC (2007) Identification of medically important Candida and non-candida yeast species by an oligonucleotide array. J Clin Microbiol 45: Lee MK, Williams LE, Warnock DW, Arthington-Skaggs BA (2004) Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 53: Lo HJ, Ho AH, Ho M (2001) Factors accounting for mis-identification of Candida species. J Microbiol Immunol Infect 34: Lo HJ, Cheng HH, TSARY Hospitals (2005) Distribution of clinical yeasts in Taiwan. Fung Sci 20: Marr KA, Lyons CN, Ha K, Rustad TR, White TC (2001) Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 45: Orozco AS, Higginbotham LM, Hitchcock CA, Parkinson T, Falconer D, Ibrahim AS, Ghannoum MA, Filler SG (1998) Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 42: Peman J, Canton E, Gobernado M (2005) Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 24: Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA (1999) Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 33: Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ (2000) Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, Antimicrob Agents Chemother 44: Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ (2003) Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, J Clin Microbiol 41: Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, Diekema DJ (2004) In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 48: Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ (2007a) In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46: Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E (2007b) Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 45: Prasad KN, Agarwal J, Dixit AK, Tiwari DP, Dhole TN, Ayyagari A (1999) Role of yeasts as nosocomial pathogens and their susceptibility to fluconazole and amphotericin B. Indian J Med Res 110: Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation a prospective, randomized, double-blind study. J Infect Dis 171: St Germain G, Laverdiere M, Pelletier R, Bourgault AM, Libman M, Lemieux C, Noel G (2001) Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 39: Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ (1998) Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26: Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E (2004) Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 10(Suppl 1): Wang JS, Li SY, Yang YL, Chou HH, Lo HJ (2007) Association between fluconazole susceptibility and genetic relatedness among Candida tropicalis isolates in Taiwan. J Med Microbiol 56: White TC, Marr KA, Bowden RA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11: Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: Yang YL, Lo HJ (2001) Mechanisms of antifungal agent resistance. J Microbiol Immunol Infect 34: Yang YL, Cheng HH, Lo HJ (2004a) In vitro activity of voriconazole against Candida species isolated in Taiwan. Int J Antimicrob Agents 24: Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ (2004b) Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 25: Yang YL, Ho YA, Cheng HH, Lo HJ (2005a) Distribution and susceptibility to amphotericin B and fluconazole of Candida spp. isolated from Taiwan. Epidemiol Infect 133: Yang YL, Li SY, Cheng HH, Lo HJ (2005b) Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY Diagn Microbiol Infect Dis 51: Yang YL, Cheng HH, Lo HJ (2006) Distribution and antifungal susceptibility of Candida species isolated from different age populations in Taiwan. Med Mycol 44:
Received 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationSpecies distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002
Fluconazole J Microbiol Immunol susceptibility Infect of Candida 2004;37:236-241 Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002 Jiun-Ling Wang
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More informationReceived 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationCandida albicans 426 (64.0 ) C. albicans non-albicans
74 2006 1) 2) 1) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 17 9 26 18 3 8 2003 10 2004 3 6 9,083 666 (7.3 ) Candida albicans 426 (64.0 ) C. albicans non-albicans 233 (35.0 ) Non-albicans Candida glabrata Candida tropicalis
More informationDistribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999
Diagnostic Microbiology and Infectious Disease 48 (2004) 33 37 Mycology Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999 Ming-Fang Cheng a,b,c,e, Kwok-Woon
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationAvailable online at journal homepage:
Kaohsiung Journal of Medical Sciences (2012) 28, 306e315 Available online at www.sciencedirect.com journal homepage: http://www.kjms-online.com ORIGINAL ARTICLE Fluconazole exposure rather than clonal
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationReceived 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 858 864 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01900-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Correlation
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationReceived 25 September 2006/Returned for modification 4 December 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 796 802 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01986-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationInterpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2006, p. 435 447 Vol. 19, No. 2 0893-8512/06/$08.00 0 doi:10.1128/cmr.19.2.435 447.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Interpretive
More informationReceived 21 July 2008/Accepted 3 September 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2008, p. 3585 3590 Vol. 46, No. 11 0095-1137/08/$08.00 0 doi:10.1128/jcm.01391-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Validation
More informationAmphotericin B, antifungal susceptibility, bloodstream infections, Candida spp., posaconazole, sus-
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01310.x Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital A. Bedini 1, C. Venturelli 2, C. Mussini 1, G.
More informationon December 11, 2018 by guest
JCM Accepts, published online ahead of print on 12 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.03125-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Biographical Feature;
More informationComparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species
NEW MICROBIOLOGICA, 31, 257-262, 2008 Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species Anna Serefko, Renata Los, Anna
More informationEpidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients
OPEN (2017) 6, e87; doi:10.1038/emi.2017.74 www.nature.com/emi ORIGINAL ARTICLE Epidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients Ping-Feng
More informationJapan Antifungal Surveillance Program (1):
183 Japan Antifungal Surveillance Program (1): 2001 2002 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 16 9 14 16 10 12 2001 6 2002 3 2 11 576 fluconazole (FLCZ),
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationRapid Identification and Antifungal Susceptibility Pattern of Candida Isolates from Critically Ill Patients with Candiduria
Original Article Vol. 26 No. 2 Rapid identification and antifungal susceptibility pattern of Candida isolates:- Chaudhary U, et al. 49 Rapid Identification and Antifungal Susceptibility Pattern of Candida
More informationReceived 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 70 75 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.01551-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Use of Fluconazole
More informationAntifungal susceptibility testing using the E test: comparison with the broth macrodilution technique
Journal of Antimicrobial Chemotherapy (996) 7, 65-7 Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique Sharon C. A. Chen, Maryann L. O'Donnell, Suzannah
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationEchinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden
JOURNAL OF CLINICAL MICROBIOLOGY, July 2011, p. 2516 2521 Vol. 49, No. 7 0095-1137/11/$12.00 doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationDistribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital,
International Journal of Infectious Diseases (2007) 11, 239 244 http://intl.elsevierhealth.com/journals/ijid Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital,
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01268.x Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital R. Luzzati 1,2, B. Allegranzi 1, L. Antozzi 1, L.
More informationReceived 5 August 2004/Accepted 26 September 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 512 517 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.512 517.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationReceived 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 561 566 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.01079-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Candida
More informationNational Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention Invasive Candidiasis
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationSYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II
SYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II DURAN NIZAMI 1, MUZ MUSTAFA 2, DURAN GULAY GULBOL 3, OZER BURCIN 1, ONLEN YUSUF 4 1 Mustafa
More information9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Invasive Candidiasis Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationThis is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Clinical Medicine Insights: Therapeutics Original Research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Impact of the New Clinical Breaking Points Proposed
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationTriazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2006, p. 529 535 Vol. 44, No. 2 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.2.529 535.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Triazole
More informationAntifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients
ISSN: 2319-7706 Volume 4 Number 3 (2015) pp. 716-720 http://www.ijcmas.com Original Research Article Antifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients Deepak Kumar 1, Sayan
More informationAntifungal Susceptibility Testing of Candida Isolates from the Candida Surveillance Study
Antifungal Susceptibility Testing of Candida Isolates from the Candida Surveillance Study G Marshall Lyon III, Emory University Sulaiman Karatela, Emory University Susan Sunay, Emory University Yaffa Adiri,
More informationDepartment of Medical Mycology and Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran 3
Curr Med Mycol, 2016 Jun, 2(2): 34-39 Article Original In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran Shokohi T 1,2, Badali H 1,2, Amirrajab N 3, Ataollahi MR
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationEvaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility
Journal of Antimicrobial Chemotherapy (2008) 62, 1094 1100 doi:10.1093/jac/dkn304 Advance Access publication 25 July 2008 Evaluation of aminocandin and caspofungin against Candida glabrata including isolates
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationResearch Article In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed by the Reference Broth Microdilution Method
The Scientific World Journal Volume 2013, Article ID 236903, 6 pages http://dx.doi.org/10.1155/2013/236903 Research Article In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed
More informationUpdate zu EUCAST 2012 Cornelia Lass-Flörl
Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationIdentification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey
DOI 10.1186/s12941-016-0153-1 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Identification and antifungal susceptibility of Candida species isolated from bloodstream infections
More informationReceived 29 October 2009/Returned for modification 4 January 2010/Accepted 9 February 2010
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2010, p. 1366 1377 Vol. 48, No. 4 0095-1137/10/$12.00 doi:10.1128/jcm.02117-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Results from
More informationSensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure
Basic research Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure Anna Serefko, Anna Malm Department of Pharmaceutical Microbiology, Medical
More informationBSI. Candida auris: A globally emerging multidrug-resistant yeast 5/19/2017. First report of C. auris from Japan in 2009
5/9/7 BSI Candida auris: A globally emerging multidrug-resistant yeast Mycotic Diseases Branch DFWED Friday Seminar August 6, 6 National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationHideyo Yamaguchi 1, Katsuhisa Uchida 1, Yayoi Nishiyama 1 and the Japan Antifungal Surveillance Program Group
Medical Mycology Research Vol. 3 No. 1: 17-26, 2012 ISSN 1883-3195 Original Articles Species distribution and in vitro susceptibility to three antifungal triazoles of clinical Candida isolates from a five-year
More informationFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah
More informationInvasive Candida infections in children: the clinical characteristics and species distribution and antifungal susceptibility of Candida spp.
The Turkish Journal of Pediatrics 20; 53: 489-498 Original Invasive Candida infections in children: the clinical characteristics and species distribution and antifungal susceptibility of Candida spp. Nurşen
More informationJCM Accepts, published online ahead of print on 3 February 2010 J. Clin. Microbiol. doi: /jcm
JCM Accepts, published online ahead of print on 3 February 2010 J. Clin. Microbiol. doi:10.1128/jcm.02363-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationRapid Antifungal Susceptibility Determination for Yeast Isolates by Use of Etest Performed Directly on Blood Samples from Patients with Fungemia
JOURNAL OF CLINICAL MICROBIOLOGY, June 2010, p. 2205 2212 Vol. 48, No. 6 0095-1137/10/$12.00 doi:10.1128/jcm.02321-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Rapid Antifungal
More informationReceived 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1396 1400 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01512-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationRapid Acquisition of Stable Azole Resistance by Candida glabrata Isolates Obtained before the Clinical Introduction of Fluconazole
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 783 787 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.783 787.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationFluconazole Susceptibility Profile of Candida isolates Recovered from Patients Specimens Admitted to Yazd Central Laboratory
Iranian Journal of Pharmaceutical Research (2008), 7 (1): 69-75 Received: June 2007 Accepted: November 2007 Copyright 2008 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationEpidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review
Epidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review Haydar A a a Department of Internal Medicine, Kulliyyah of Medicine,
More informationCandidemia: New Sentinel Surveillance in the 7-County Metro
Candidemia: New Sentinel Surveillance in the 7-County Metro Brittany VonBank, MPH Paula Vagnone, MT (ASCP) 651-201-5414 www.health.state.mn.us Health Care-associated Infections & Antimicrobial Resistance
More informationPREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI
Shrutika Wandre et al. Special Issue, 2015, pp. 25-36 PREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI Shrutika Wandre Department of Clinical Pathology, Haffkine Institute for Training, Research and Testing,
More informationANA ESPINEL-INGROFF* Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 198 202 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activity of the New Triazole Voriconazole (UK-109,496)
More informationReceived 15 October 2001/Returned for modification 27 May 2002/Accepted 24 June 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2002, p. 3268 3272 Vol. 46, No. 10 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.10.3268 3272.2002 Copyright 2002, American Society for Microbiology. All Rights
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More informationSusceptibility of Candida Species Isolated From HIV Infected and Newborn Candidaemia Patients to Amphotericin B
OnLine Journal of Biological Sciences 10 (2): 109-113, 2010 ISSN 1608-4217 2010 Science Publications Susceptibility of Candida Species Isolated From HIV Infected and Newborn Candidaemia Patients to Amphotericin
More informationCandidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex
Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex ORIGINAL ARTICLE ABSTRACT Introduction: Although the spectrum of fungi causing bloodstream fungal infections
More informationThe antifungal susceptibilities of oral Candida spp isolates from HIV-infected patients
Advanced Journal of Microbiology Research Volume 2015 Available online at http://advancedresearchjournals.org/ajmr Advanced Research Journals Full Length Research Paper The antifungal susceptibilities
More informationDistribution of clinical yeasts in Taiwan
Fung. Sci. 20(3 4): 83 91, 2005 Distribution of clinical yeasts in Taiwan Hsiu-Jung Lo, Hsiao-Hsu Cheng, and TSARY Hospitals Division of Clinical Research, National Health Research Institutes, 35, Keyan
More informationon December 9, 2018 by guest
JCM Accepts, published online ahead of print on 27 June 2012 J. Clin. Microbiol. doi:10.1128/jcm.00937-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Progress in Antifungal
More informationCandida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains
Medical Mycology March 2009, 47, 137143 Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains MARÍA MERCEDES PANIZO, VERA REVIÁKINA,
More informationSpecies Distribution and Antifungal Drug Susceptibility of Candida in Clinical Isolates from a Tertiary Care Centre at Bareilly
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 1 Ver. II (January. 2017), PP 57-61 www.iosrjournals.org Species Distribution and Antifungal
More informationMultilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1543 1548 Vol. 55, No. 4 0066-4804/11/$12.00 doi:10.1128/aac.01510-09 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multilaboratory
More informationCandida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital
ORIGINAL ARTICLE MYCOLOGY Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital P. Muñoz, M. Giannella, C. Fanciulli, J. Guinea, M. Valerio, L. Rojas, M. Rodríguez-Créixems
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2000, p Vol. 44, No. 8
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2000, p. 2081 2085 Vol. 44, No. 8 0066-4804/00/$04.00 0 Quantitation of Candida albicans Ergosterol Content Improves the Correlation between In Vitro Antifungal
More informationLaboratory evaluation for determining posaconazole susceptibility of fungi isolated in denture stomatitis
Experimental immunology DOI: 10.5114/ceji.2013.35209 Laboratory evaluation for determining posaconazole susceptibility of fungi isolated in denture stomatitis MARTA JAWORSKA-ZAREMBA 1, EL BIETA MIERZWIÑSKA-NASTALSKA
More informationRapid Species Identification and Antifungal Susceptibility Testing of Candida Isolated from Different Hospital Acquired Infections by VITEK 2 System
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 11 (2017) pp. 764-772 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.611.090
More informationPREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI
Wandre et al., 2015 Volume 1 Issue 1, pp. 25-36 Year of Publication: 2015 DOI- https://dx.doi.org/10.20319/lijshls.2015.s11.2536 This paper can be cited as: Wandre, S., Sanap, S., Mukadam, T., Vaidya,
More informationAnidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies
Received: 1 February 2017 Revised: 11 May 2017 Accepted: 11 May 2017 DOI: 10.1111/myc.12641 ORIGINAL ARTICLE Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled
More informationUpdated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017
Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline
More informationTreatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2005, p. 4895 4902 Vol. 49, No. 12 0066-4804/05/$08.00 0 doi:10.1128/aac.49.12.4895 4902.2005 Treatment of Candida glabrata Infection in Immunosuppressed Mice
More informationOpen. Abstract. Access
MICROBIOZ JOURNALS Open Access Volume: 1st, Issue: 5 th Microbioz Journals, Journal Of Microbiology and Biomedical Research An open access peer reviewed International Journal Available on : www.microbiozjournals.com
More informationyour lab focus susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal testing.
626 CE update [microbiology and virology] Antifungal Susceptibility Methods and Their Potential Clinical Relevance Ana Espinel-Ingroff, PhD Medical College of Virginia, Virginia Commonwealth University,
More informationAAC Accepts, published online ahead of print on 21 March 2011 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 1 March 0 Antimicrob. Agents Chemother. doi:./aac.010- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationon March 29, 2019 by guest
JCM Accepts, published online ahead of print on 4 May 2011 J. Clin. Microbiol. doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationQuantitation of Ergosterol Content: Novel Method for Determination of Fluconazole Susceptibility of Candida albicans
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 1999, p. 3332 3337 Vol. 37, No. 10 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Quantitation of Ergosterol Content:
More informationReceived 24 September 2001/Returned for modification 2 February 2002/Accepted 31 May 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2002, p. 2982 2989 Vol. 46, No. 9 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.9.2982 2989.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationmycoses Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya Summary Introduction
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya Rennatus Mdodo,
More informationOccurrence of Drug Resistant Candida Species in the Sputum of TB Clinic Attendees in and Around Chidambaram, Tamilnadu, India
Journal of Experimental Sciences Vol. 1, Issue 4, Pages 43-47 [2010] www.jexpsciences.com Regular Article Occurrence of Drug Resistant Candida Species in the Sputum of TB Clinic Attendees in and Around
More information